. BurrisKD, MolskiTF, XuC, RyanE, TottoriK, KikuchiT, Aripiprazole, a novel antipsychotic, is a high affinity partial agonist at human dopamine D 2 receptors. J Pharmacol Exp Ther2002; 302: 381–9.
2.
. JordanS, KoprivicaV, ChenR, TottoriK, KikuchiT, AltarCA. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT 1A receptor. Eur J Pharmacol2002; 441: 137–40.
3.
. PotkinSG, SahaAR, KujawaMJ, CarsonWH, AliM, StockE, Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry2003; 60: 681–90.
4.
. KeckPE, MarcusR, TourkodimitrisS, AliM, LiebeskineA, SahaA, A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry2003; 160: 1651–8.
5.
. DavenportJD, McCarthyMW, BuckML. Excessive somnolence from aripiprazole in a child. Pharmacotherapy2004; 24: 522–5.
